online ISSN 2415-3176
print ISSN 1609-6371
logoExperimental and Clinical Physiology and Biochemistry
  • 10 of 16
Up
ECPB 2016, 73(1): 68–73
https://doi.org/10.25040/ecpb2016.01.068
Clinical physiology and biochemistry

Influence of Hemodialysis Catecholamine Levels in the Blood Plasma of Patients with Chronic Renal Failure

ІVANOCHKO R.1, DZIEDZIC M.2, SOLSKI J.2, SKLYAROV O.1
Abstract

Chronic renal failure (CRF) is one of the fastest growing global and kidney abnormalities that have poor prognosis and high mortality of patients. Manifestations of chronic renal failure include various metabolic disorders, primarily growth of toxic products (urea, uric acid, creatinine, indican). CRF is characterized by endothelial dysfunction, hypertension, changes in platelet function, increased blood levels of markers of inflammation and oxidative stress, which causes dysfunction of the sympathetic division of the autonomic nervous system.

Among the risk factors of death in patients with chronic renal failure is not only an increase of levels of toxic substances in blood, and the development of cardiovascular disease, which in 59 % of cases causes death. Cardiovascular disease include both direct change of heart and kidney disease, endothelial dysfunction, increased blood pressure and the development of inflammation – the emergence nitrozo-oxidative stress and increased levels of proinflammatory cytokines.

Among the factors, that directly influence on the cardiovascular system in patients with chronic renal failure is the level of catecholamines in blood. Increased activity of the sympathetic division of the autonomic nervous system will cause increase in the allocation of catecholamines in the blood that are released into the blood from the adrenal glands.

In 37 patients with chronic renal failure, the content of catecholamines (dofamіn, noradrenalіn and adrenalіn) before and after hemodialysis was determined. Duration of dialysis was on average 4,6 ± 0,2 hours. We used methods of dialysis low flux (19 patients) and high-flux (18 patients) with the use of dialyzers with high permeability. It is shown that the concentration of norepinephrine in the plasma of patients with end-stage renal failure was significantly higher, whereas the concentration of adrenaline and dopamine does not differ from the control group. There was no statistically significant difference in the concentration of catecholamines in men and women with chronic renal failure as compared to the control group. After hemodialysis, the patients with end-stage renal failure showed decreased plasma norepinephrine concentration in comparison with its contents before the procedure. The concentrations of adrenaline and dopamine plasma randomness did not change before and after hemodialysis. With this respect, plasma concentrations of norepinephrine and dopamine, in patients with CRF receiving dialysis therapy, their content was significantly increased compared with the patients with end-stage renal failure. Conducting a session of dialysis resulted in lower plasma concentrations of norepinephrine. In our studies we noted an increased content of norepinephrine, whereas the concentration of dopamine and adrenaline statistically unchanged.

Consequently, our research shows that among the studied concentration of catecholamines noradrenaline only in the blood plasma of the patients with end-stage growing, which is one of the risk factors for complications of the cardiovascular system. Hemodialysis session reduces the concentration of norepinephrine in the plasma.

Keywords: hemodialysis, chronic renal failure, catecholamines, oxidative stress

Full text: PDF (Ukr) 949K

References
  1. 1.Korol' L, Myhal' L, Dudar I, Gonchar Y. Antioxidant system, ceruloplasmin, transferrin and status komorbitnosti in patients with chronic kidney disease who are treated with hemodialysis. Ukrainian Journal of Nephrology and dialysis. 2011;4:35-39.
  2. 2.Ivanochko R, Biletska L, Sklyarov A. Changes indicators of l-arginine/nitric nitrogen/arginase and oxidative processes in the plasma of patients with chronic renal failure before and after hemodialysis. Experimental and clinical physiology. 2014;1:66-71.
  3. 3.Dudar I, Loboda A, Korol' L, Alekseeva V. The progression of chronic kidney disease: state of oxidative stress in different stages of CKD. Ukrainian Journal of Nephrology and Dialysis. 2012;2:18-24.
  4. 4. Errakonda P, Paladugu R, Bitla A, Musturu S, Lakshman J, Pemmaraju S et al. Effect of a single hemodialysis session on endothelial dysfunction. J Nephrol. 2011;24(1):83-90. doi.org/10.5301/JN.2010.4926
  5. 5. Grekas D, Kalevrosoglou I, Karamouzis M, Geropoulou E, Kabouris H, Tourkantonis A. Effect of sympathetic and plasma renin activity on hemodialysis hypertension. Clin Nephrol. 2001;55(2):115-120.
  6. 6. Elias A, Vaziri N, Maksy M. Plasma norepinephrine, epinephrine, and dopamine levels in end-stage renal disease. Effect of hemodialysis. Arch Intern Med. 1985;145(6):1013-1015. doi.org/10.1001/archinte.1985.00360060069008
  7. 7. Georgianos P, Sarafidis P, Zoccali C. Intradialysis Hypertension in End-Stage Renal Disease Patients: Clinical Epidemiology, Pathogenesis, and Treatment. Hypertension. 2015;66(3):456-463. doi.org/10.1161/HYPERTENSIONAHA.115.05858
  8. 8. Hon W, Lee J, Lee K. Effect of hemodialysis on plasma nitric oxide levels. Artif Organs. 2000;24(5):387-390. doi.org/10.1046/j.1525-1594.2000.06496-2.x
  9. 9. Oberg B, McMenamin E, Lucas F, McMonagle E, Morrow J, Ikizler T et al. Increased prevalence of oxidant stress, and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004;65:1009-1016. doi.org/10.1111/j.1523-1755.2004.00465.x
  10. 10. Montezano A, Touyez R. Molecular mechanisms of hypertension: reactive oxygen species and antioxidants: a basic science update for the clinician. Can J Cardiol. 2011;28:288-295. doi.org/10.1016/j.cjca.2012.01.017
  11. 11. Dziedzic M, Bednarek-Skublewska A, Solski J, Kapka-Skrzypczak L. Plasma and erythrocyte relationship of catecholamines in haemodialysis patients. Ann Agr Env Med. 2014;21(3):565-566. doi.org/10.5604/12321966.1120602
  12. 12. Dziedzic M, Orlowska E, Gawel K., Zawadzka M, Bednarek-Skublewska A, Solski J. Plasma levels of catecholamines and asymmetric dimethylarginine levels as predictive values of mortality among hemodialysis patients. Curr Iss Pharm Med Sci. 2014;27(1):37–40.
  13. 13. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto F, Tripepi G et al. Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease. Circulation. 2002;105(11):1354-1359. doi.org/10.1161/hc1102.105261
  14. 14. Zimmerman D, Ruzicka M, Hebert P, Fergusson D, Touyz R, Burns K et al. Short Daily versus Conventional Hemodialysis for Hypertensive Patients: A Randomized Cross-Over Study. PLoS One. 2014;9(5):e97135. doi.org/10.1371/journal.pone.0097135
  15. 15. Taal M. Chronic kidney disease in older people - diagnosis, etiology and consequences. Curr Opin Nephrol Hypertens. 2015;24(6):475-479. doi.org/10.1097/MNH.0000000000000164
  16. 16. Brunini T, da Silva C, Siqueira M, Moss M, Santos S, Mendes-Ribeiro A et al. Uremia, atherothrombosis and malnutrition: the role of L-arginine-nitric oxide pathway. Cardiovasc Hematol Disord Drug Targets. 2006;6(2):133-140. doi.org/10.2174/187152906777441821


Програмування - Roman.im